Comparing the current results to its competitors, Zivo Bioscience Inc reported Revenue increase in the 3 quarter 2025 by 108.33 % year on year. The sales growth was above Zivo Bioscience Inc 's competitors' average revenue growth of 0.83 %, achieved in the same quarter.
Zivo Bioscience Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 6.02 %
Zivo Bioscience Inc 's Comment on Competition and Industry Peers
The competitive landscape encompasses companies involved in homeopathic and natural remedies, large pharmaceutical and biopharmaceutical firms, specialty pharmaceutical and generic drug companies, academic institutions, government agencies, and research organizations. Key competitors in poultry gut health and avian influenza include HuvePharma, Elanco, Zoetis, and Phibro. In No Antibiotics Ever (NAE) poultry production, alternatives consist of vaccines, antimicrobial chemicals, and products offered by ZIVO. For bovine mastitis, branded antibiotic solutions such as ToDay are available. In the human food and food ingredients sector, competitors include Earthrise, Cyanotech, AG1, DSM, Cognis, ConAgra, Cargill, and Nestle. The skin health and anti-aging markets feature various topical treatments and dietary supplements, including Well Roots Biotin Rich Plus Collagen, Heliocare Skin Care Dietary Supplement, CoQ10 Supplement, Vitamin C, Peptan®, Verisol®, and Pure Gold Collagen®.
September 10, 2025
In an era where the intersection of health and technology continues to reshape industries, ZIVO Bioscience, Inc. (OTCQB: ZIVO) emerges as a standout player in the biotech and agtech sectors. With a focus on the development of therapeutic and nutritional products derived from proprietary algal cultures, the company s recent advancements highlight a promising trajectory that could redefine both human nutrition and animal therapeutics.In a recent letter to shareholders, John B. Payne, the Chairman, President, and CEO of ZIVO, expressed his enthusiasm regarding the significant progress the company has made over recent months. This update not only reaffirms ZIVO’s commitment to its innovation and growth strate...
July 8, 2024
Major Global Animal Health Company Collaborates with ZIVO Biosciences for Coccidiosis StudyBLOOMFIELD HILLS, Mich. ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a leading biotech/agtech RandD company focused on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced the commencement of a 42-day confirmatory study in partnership with a major global animal health company. This study aims to further validate the efficacy of ZIVO s non-antibiotic, immune-modulating product for the treatment of coccidiosis in broiler chickens.Coccidiosis is a highly contagious intestinal disease that affects poultry and other animals, causing significant economic losses for far...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
DuPont De Nemours Inc operates as a diversified science and technology company, leveraging advanced materials and innovative solutions to serve multiple industries such as agriculture, electronics, transportation, and healthcare. The companys business model emphasizes sustainability and innovation, aiming to meet the evolving needs of its customers while addressing global challenges.
Sources:
Zivo Bioscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zivo Bioscience Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
